Ixazomib
- Generic Name
- Ixazomib
- Brand Names
- Ninlaro
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19BCl2N2O4
- CAS Number
- 1072833-77-2
- Unique Ingredient Identifier
- 71050168A2
- Background
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...
- Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- Associated Conditions
- Multiple Myeloma (MM)
- Associated Therapies
- -
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- H Scott Boswell
- Target Recruit Count
- 8
- Registration Number
- NCT04079738
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Larysa Sanchez
- Target Recruit Count
- 18
- Registration Number
- NCT04052880
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04047797
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bone Healing During Ninlaro Exposure
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Thomas Lund
- Target Recruit Count
- 30
- Registration Number
- NCT04028115
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 79
- Registration Number
- NCT04009109
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Northern Light Eastern Maine Medical Center, Bangor, Maine, United States
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 49
- Registration Number
- NCT03942224
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT03888534
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇪🇸Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain
Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Matthew Ingham
- Registration Number
- NCT03880123
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03856112
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-02-22
- Target Recruit Count
- 31
- Registration Number
- NCT03817320
- Locations
- 🇺🇸
Texas Children's Hospital/Baylor University, Houston, Texas, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.